Fumigaclavine C inhibits tumor necrosis factor α production via suppression of toll-like receptor 4 and nuclear factor κb activation in macrophages

Life Sciences

Volumn 89, Issue 7-8, 2011, Pages 235-240

  Du, Rong Hui ^a   Li, Er Guang ^a   Cao, Yin ^a   Song, Yong Chun ^a   Tan, Ren Xiang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Atherosclerosis; Fumigaclavine C; NF B; TLR4; TNF

Indexed keywords

CURCUMIN; FUMIGACLAVINE C; FUNGAL ENZYME; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG SCREENING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL SURVIVAL; CURCUMIN; ERGOT ALKALOIDS; HEK293 CELLS; HUMANS; INDOLE ALKALOIDS; MACROPHAGES; MICE; NF-KAPPA B; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960984398     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.06.015     Document Type: Article

References (32)

1. Ahmad S, Israf DA, Lajis NH, Shaari K, Mohamed H, Wahab AA, Ariffin KT, Hoo WY, Aziz NA, Kadir AA, Sulaiman MR, Somchit MN. Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood. Eur J Pharmacol 2006;538 (1-3):188-94.
2. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242(4878):540-6. (Pubitemid 18263193)
3. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995;15(5):2809-18.
4. Brunialti MK, Kallas EG, Freudenberg M, Galanos C, Salomao R. Influence of EDTA and heparin on lipopolysaccharide binding and cell activation, evaluated at single-cell level in whole blood. Cytometry 2002;50(1):14-8. (Pubitemid 37509476)
5. Denk A, Wirth T, Baumann B. NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev 2000;11(4):303-20.
6. Desai MS, Mariscalco MM, Tawil A, Vallejo JG, Smith CW. Atherogenic diet-induced hepatitis is partially dependent on murine TLR4. J Leukoc Biol 2008;83(6):1336-44. (Pubitemid 351960312)
7. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000;275(15):11058-63. (Pubitemid 30212746)
8. Finco TS, Beg AA, Baldwin AS. Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. Proc Natl Acad Sci U S A 1994;91(25):11884-8. (Pubitemid 24368568)
9. Foss NT, Foss-Freitas MC, Ferreira MA, Cardili RN, Barbosa CM, Foss MC. Impaired cytokine production by peripheral blood mononuclear cells in type 1 diabetic patients. Diabetes Metab 2007;33(6):439-43. (Pubitemid 350213453)
10. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97(15):1436-9. (Pubitemid 28191297)
11. Heo SK, Yun HJ, Noh EK, Park WH, Park SD. LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol Lett 2008;120(1-2):57-64.
12. Jackson L, Cady CT, Cambier JC. TLR4-mediated signaling induces MMP9-dependent cleavage of B cell surface CD23. J Immunol 2009;183(4):2585-92.
13. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. (Pubitemid 351482735)
14. Li H, Cao MY, Lee Y, Benatar T, Lee V, Feng N, Gu X, Liu P, Jin H, Wang M, Der S, Lightfoot J, Wright JA, Young AH. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo. Int Immunopharmacol 2007;7(10):1350-9. (Pubitemid 47126374)
15. Lubbad A, Oriowo MA, Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009;322(1-2):127-35.
16. MaHY, Song YC, Mao YY, Jiang JH, Tan RX, Luo L. Endophytic fungalmetabolite fumigaclavine C causes relaxation of isolated rat aortic rings. Planta Med 2006;72(5):387-92.
17. Manderson AP, Kay JG, Hammond LA, Brown DL, Stow JL. Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFalpha. J Cell Biol 2007;178(1):57-69. (Pubitemid 47026402)
18. Meier A, Kirschning CJ, Nikolaus T, Wagner H, Heesemann J, Ebel F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 2003;5(8):561-70. (Pubitemid 36939595)
19. Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004;173(10):5901-7. (Pubitemid 39487741)
20. Miggin SM, O'Neill LA. New insights into the regulation of TLR signaling. J Leukoc Biol 2006;80(2):220-6. (Pubitemid 44835495)
21. Ohtake N, Suzuki R, Daikuhara H, Nakai Y, Yamamoto M, Amagaya S, Ishige A, Sasaki H, Komatsu Y, Fukuda K, Hayashi S. Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to. Int J Immunopharmacol 2000;22(6):419-30. (Pubitemid 30155751)
22. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004;34(5):328-34. (Pubitemid 38748072)
23. Profumo E, Esposito C, Buttari B, Tosti ME, Ortona E, Margutti P, Siracusano A, Sposato A, Costanzo A, Capoano R, Salvati B, Rigano R. Intracellular expression of cytokines in peripheral blood from patients with atherosclerosis before and after carotid endarterectomy. Atherosclerosis 2007;191(2):340-7. (Pubitemid 46400694)
24. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340(2):115-26. (Pubitemid 29054847)
25. Rossebo A, Pedersen T, Boman K. Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Eng J Med 2008;359:1343-56.
26. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 1990;171(1):35-47. (Pubitemid 20040597)
27. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108(4):426-31. (Pubitemid 36935535)
28. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992;36(4):273-5. (Pubitemid 23031285)
29. Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM, Brennan FM. Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. Rheumatology (Oxford) 2009;48(1):32-8.
30. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978;43:86-92. (Pubitemid 9016316)
31. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997;278(5339):866-9. (Pubitemid 27467924)
32. Wu XF, Fei MJ, Shu RG, Tan RX, Xu Q. Fumigaclavine C, an fungal metabolite, improves experimental colitis in mice via downregulating Th1 cytokine production and matrix metalloproteinase activity. Int Immunopharmacol 2005;5(10):1543-53. (Pubitemid 40967912)